{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:09:10Z","timestamp":1791212950624,"version":"4.1.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.rmr.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T10:00:10Z","timestamp":1480068010000},"page":"911-936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise"],"prefix":"10.1016","volume":"33","author":[{"given":"M.","family":"Zysman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Housset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Morelot-Panzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2016.10.004_bib0585","author":"GOLD"},{"key":"10.1016\/j.rmr.2016.10.004_bib0590","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.rmr.2012.05.012","article-title":"Position de la Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise vis-\u00e0-vis de la version 2011 des recommandations GOLD","volume":"29","author":"Roche","year":"2012","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2016.10.004_bib0595","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0600","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"ones","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0605","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.rmed.2012.08.022","article-title":"Indacaterol therapy in patients with COPD not receiving other maintenance treatment","volume":"106","author":"Decramer","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0610","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0615","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0620","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/COPD.S61717","article-title":"Efficacy and safety of olodaterol once daily delivered via Respimat(R) in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Ferguson","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2016.10.004_bib0625","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3109\/15412555.2014.991864","article-title":"One-year safety of olodaterol once daily via Respimat(R) in patients with GOLD 2-4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis","volume":"12","author":"McGarvey","year":"2015","journal-title":"COPD"},{"key":"10.1016\/j.rmr.2016.10.004_bib0630","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S62502","article-title":"Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Koch","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2016.10.004_bib0635","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0640","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1183\/09031936.00127809","article-title":"Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial","volume":"36","author":"Troosters","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0645","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0650","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0655","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1183\/09031936.00040712","article-title":"Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study","volume":"40","author":"Kerwin","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0660","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1183\/09031936.00033213","article-title":"Umeclidinium in patients with COPD: a randomised, placebo-controlled study","volume":"43","author":"Trivedi","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0665","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00225511","article-title":"Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study","volume":"40","author":"Jones","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0670","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/15412555.2015.1074172","article-title":"Efficacy and safety of an aclidinium bromide treatment for 12 weeks or longer in patients with moderate-to-severe COPD: a meta-analysis","volume":"13","author":"Zou","year":"2016","journal-title":"COPD"},{"key":"10.1016\/j.rmr.2016.10.004_bib0675","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/15412555.2013.814626","article-title":"Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study","volume":"10","author":"Beier","year":"2013","journal-title":"COPD"},{"key":"10.1016\/j.rmr.2016.10.004_bib0680","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1183\/09031936.00005813","article-title":"Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD","volume":"42","author":"Verhamme","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0685","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa1303342","article-title":"Tiotropium Respimat inhaler and the risk of death in COPD","volume":"369","author":"Wise","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0690","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1378\/chest.129.3.509","article-title":"Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD","volume":"129","author":"van Noord","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib0695","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","volume":"42","author":"Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0700","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0705","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","article-title":"Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study","volume":"43","author":"Mahler","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0710","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.rmed.2013.06.001","article-title":"Efficacy and safety of once-daily umeclidinium\/vilanterol 62.5\/25 mcg in COPD","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0715","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","article-title":"Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials","volume":"2","author":"Decramer","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0720","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40268-016-0131-2","article-title":"Dual bronchodilator therapy with umeclidinium\/vilanterol versus tiotropium plus indacaterol in chronic obstructive pulmonary disease: a randomized controlled trial","volume":"16","author":"Kalberg","year":"2016","journal-title":"Drugs R D"},{"key":"10.1016\/j.rmr.2016.10.004_bib0725","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12931-014-0123-0","article-title":"Efficacy and safety of fixed-dose combinations of aclidinium bromide\/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study","volume":"15","author":"D\u2019Urzo","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2016.10.004_bib1165","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","article-title":"Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)","volume":"45","author":"Buhl","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0735","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","article-title":"A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD","volume":"149","author":"Calzetta","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib0740","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1753465815624612","article-title":"Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis","volume":"10","author":"Schlueter","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.rmr.2016.10.004_bib0745","first-page":"CD008989","article-title":"Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease","volume":"10","author":"Farne","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2016.10.004_bib0750","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","article-title":"Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis","volume":"71","author":"Oba","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib0755","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0760","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0765","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2008.717","article-title":"Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Drummond","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2016.10.004_bib0770","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0775","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial","volume":"353","author":"Vestbo","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.10.004_bib0780","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.rmr.2016.10.004_bib0785","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.10.004_bib0790","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9343(02)01143-9","article-title":"The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials","volume":"113","author":"Alsaeedi","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0795","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.200508-1338PP","article-title":"Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease","volume":"173","author":"Suissa","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0800","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0805","first-page":"CD007033","article-title":"Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","volume":"10","author":"Spencer","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2016.10.004_bib0810","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0815","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.10.004_bib0820","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/thoraxjnl-2012-203175","article-title":"Use of inhaled corticosteroids and the risk of tuberculosis","volume":"68","author":"Lee","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib0825","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1378\/chest.13-2137","article-title":"Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Dong","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib0830","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1183\/09031936.93.05101254","article-title":"European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design","volume":"5","author":"Pauwels","year":"1992","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0835","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0012-3692(15)31287-3","article-title":"Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II","volume":"126","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib0840","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4104\/pcrj.2012.00092","article-title":"Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD","volume":"22","author":"Price","year":"2013","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0845","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","article-title":"Inhaled corticosteroids and the risks of diabetes onset and progression","volume":"123","author":"Suissa","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0850","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.200305-640OC","article-title":"Inhaled and nasal corticosteroid use and the risk of fracture","volume":"169","author":"Suissa","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0855","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/thx.2011.160028","article-title":"Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies","volume":"66","author":"Loke","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib0860","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM199707033370102","article-title":"Use of inhaled corticosteroids and the risk of cataracts","volume":"337","author":"Cumming","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0865","first-page":"467","article-title":"Long-term use of fluticasone propionate\/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database","volume":"6","author":"Miller","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2016.10.004_bib0870","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results","volume":"34","author":"Crim","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0875","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1378\/chest.09-2992","article-title":"Reported pneumonia in patients with COPD: findings from the INSPIRE study","volume":"139","author":"Calverley","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib0880","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","article-title":"Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD","volume":"12","author":"Crim","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2016.10.004_bib0885","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","article-title":"Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis","volume":"68","author":"Andrejak","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib0890","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-8-93","article-title":"Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial","volume":"8","author":"Choudhury","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2016.10.004_bib0895","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study","volume":"166","author":"van der Valk","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0900","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0954-6111(99)90001-X","article-title":"An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease","volume":"93","author":"Jarad","year":"1999","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0905","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","article-title":"Withdrawal of inhaled glucocorticoids and exacerbations of COPD","volume":"371","author":"Magnussen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0910","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/thx.2004.034280","article-title":"Withdrawal of fluticasone propionate from combined salmeterol\/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial","volume":"60","author":"Wouters","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib0915","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1465-9921-12-107","article-title":"Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology","volume":"12","author":"Nadeem","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2016.10.004_bib0920","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1183\/09031936.00128914","article-title":"Inhaled corticosteroids in COPD: the clinical evidence","volume":"45","author":"Ernst","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0925","first-page":"CD006829","article-title":"Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease","volume":"9","author":"Nannini","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2016.10.004_bib0930","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.rmr.2010.04.012","article-title":"De nouvelles recommandations pour la prise en charge de la BPCO","volume":"27","author":"Lemarie","year":"2010","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2016.10.004_bib0935","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","article-title":"Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study","volume":"1","author":"Vogelmeier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0940","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/COPD.S95055","article-title":"The lung function profile of once-daily tiotropium and olodaterol via Respimat((R)) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler((R)) (ENERGITO((R)) study)","volume":"11","author":"Beeh","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2016.10.004_bib0945","first-page":"1015","article-title":"LANTERN: a randomized study of QVA149 versus salmeterol\/fluticasone combination in patients with COPD","volume":"10","author":"Zhong","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmr.2016.10.004_bib0950","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0955","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/resp.12646","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia","volume":"21","author":"Lee","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2016.10.004_bib0960","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0965","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/thoraxjnl-2014-206670","article-title":"Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol\/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial","volume":"70","author":"Frith","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15412555.2015.1034256","article-title":"Efficacy and safety of umeclidinium added to fluticasone propionate\/salmeterol in patients with COPD: results of two randomized, double-blind studies","volume":"13","author":"Siler","year":"2016","journal-title":"COPD"},{"key":"10.1016\/j.rmr.2016.10.004_bib0975","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2016.10.004_bib0980","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0985","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1183\/09031936.00062614","article-title":"Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis","volume":"44","author":"Bafadhel","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib0990","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib0995","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: A biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1000","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting beta-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib1005","first-page":"CD004105","article-title":"Prophylactic antibiotic therapy for chronic bronchitis","volume":"1","author":"Staykova","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2016.10.004_bib1010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","article-title":"Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial","volume":"11","author":"Sethi","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2016.10.004_bib1015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib1030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2016.10.004_bib1035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12931-016-0330-y","article-title":"Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis","volume":"17","author":"Luo","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2016.10.004_bib1040","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa1403086","article-title":"Simvastatin for the prevention of exacerbations in moderate-to-severe COPD","volume":"370","author":"Criner","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1045","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1378\/chest.09-0194","article-title":"Statins in COPD: a systematic review","volume":"136","author":"Janda","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib1050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/thoraxjnl-2015-207251","article-title":"Beta-blockers are associated with a reduction in COPD exacerbations","volume":"71","author":"Bhatt","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib1055","doi-asserted-by":"crossref","first-page":"e113048","DOI":"10.1371\/journal.pone.0113048","article-title":"Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2016.10.004_bib1060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000196540","article-title":"Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial","volume":"63","author":"Allegra","year":"1996","journal-title":"Respiration"},{"key":"10.1016\/j.rmr.2016.10.004_bib1065","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.92.4.618","article-title":"A controlled trial of ambroxol in chronic bronchitis","volume":"92","author":"Guyatt","year":"1987","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib1070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.chest.2016.04.011","article-title":"Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial","volume":"150","author":"Cosio","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2016.10.004_bib1080","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.02.03242002","article-title":"Impact of COPD in North America and Europe in 2000: subjects\u2019 perspective of Confronting COPD International Survey","volume":"20","author":"Rennard","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib1085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.20452\/pamw.915","article-title":"Management of dyspnea in patients with advanced lung or heart disease: practical guidance from the American college of chest physicians consensus statement","volume":"120","author":"Mahler","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.rmr.2016.10.004_bib1090","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thorax.57.11.939","article-title":"A systematic review of the use of opioids in the management of dyspnoea","volume":"57","author":"Jennings","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib1095","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jpainsymman.2010.11.021","article-title":"Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study","volume":"42","author":"Currow","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.rmr.2016.10.004_bib1100","doi-asserted-by":"crossref","first-page":"e006818","DOI":"10.1136\/bmjopen-2014-006818","article-title":"Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?","volume":"5","author":"Currow","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmr.2016.10.004_bib1105","doi-asserted-by":"crossref","first-page":"g7617","DOI":"10.1136\/bmj.g7617","article-title":"The management of chronic breathlessness in patients with advanced and terminal illness","volume":"349","author":"Ekstrom","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.rmr.2016.10.004_bib1110","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1164\/ajrccm.161.6.9910009","article-title":"Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea","volume":"161","author":"Nishino","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resp.2006.07.004","article-title":"Effect of inhaled furosemide on air hunger induced in healthy humans","volume":"156","author":"Moosavi","year":"2007","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.rmr.2016.10.004_bib1120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/thx.2007.085993","article-title":"Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD","volume":"63","author":"Jensen","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib1125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/thoraxjnl-2013-204701","article-title":"The active identification and management of chronic refractory breathlessness is a human right","volume":"69","author":"Currow","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib1130","series-title":"Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease","author":"Global initiative for chronic obstructive lung disease","year":"2011"},{"key":"10.1016\/j.rmr.2016.10.004_bib1135","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.rmr.2014.02.014","article-title":"La BPCO et la perception du nouveau document GOLD en Europe","volume":"31","author":"Zysman","year":"2014","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2016.10.004_bib1140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(14)70227-9","article-title":"Inhaled steroids in COPD: when should they be used?","volume":"2","author":"Agusti","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2016.10.004_bib1145","unstructured":"Guidelines Asthma, COPD, and Asthma-COPD overlap syndrome global initiative for chronic obstructive lung disease [Internet]. Disponible \u00e0 l\u2019adresse\u00a0: http:\/\/www.goldcopd.org\/asthma-copd-overlap.html."},{"key":"10.1016\/j.rmr.2016.10.004_bib1150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4104\/pcrj.2013.00016","article-title":"A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)","volume":"22","author":"Miravitlles","year":"2013","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.rmr.2016.10.004_bib1155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/thoraxjnl-2011-201458","article-title":"Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease","volume":"67","author":"Albert","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2016.10.004_bib1160","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jama.2014.11432","article-title":"Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease","volume":"312","author":"Gershon","year":"2014","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1016\/j.rmr.2017.01.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000}}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S076184251630198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S076184251630198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T21:31:59Z","timestamp":1749763919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S076184251630198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S076184251630198X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2016.10.004","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS on behalf of SPLF.","name":"copyright","label":"Copyright"}]}}